• Phytol as a Versatile RXR Activator: Mechanistic Insights an

  2026-07-24

  Explore the multifaceted role of Phytol in retinoid X receptor signaling and advanced lyotropic assay design. This article offers a deep dive into Phytol's mechanisms and practical workflows that distinguish it from conventional nuclear hormone receptor tools.

• Technical Guide: Hoechst 33342/PI Double Staining Kit (K2237

  2026-07-24

  The Hoechst 33342/PI Double Staining Kit enables rapid, fluorescence-based discrimination of viable, apoptotic, and necrotic cells by assessing nuclear morphology and membrane integrity. This kit is optimized for research use in apoptosis and necrosis studies but is not intended for diagnostic or clinical workflows. Its dual-staining approach supports clear identification of cell states in fluorescence microscopy assays.

• URB597 (KDS-4103): Precision FAAH Inhibition in Neuroinflamm

  2026-07-23

  Explore the advanced use of URB597 in endocannabinoid signaling modulation and neuroinflammation studies. This article offers unique insights into protocol optimization, translational impact, and the practical implications of FAAH inhibition in pain and affective disorder research.

• SHC-1 Inhibition Modulates CFTR Trafficking in Epithelial Ce

  2026-07-23

  This study dissects how SHC-1 inhibition via the MAPK pathway increases plasma membrane CFTR abundance in epithelial models, revealing cell-specific regulation of CFTR trafficking. The findings inform strategies to modulate CFTR in cystic fibrosis and secretory diarrhea research, while also clarifying methodological considerations for model selection.

• Angiotensin 1/2 (5-7): Workflow Innovations in RAS & COVID-1

  2026-07-22

  Angiotensin 1/2 (5-7) redefines experimental RAS and viral binding assays with unmatched solubility and purity. Harness this peptide for high-fidelity hypertension models or to dissect SARS-CoV-2 interactions, leveraging both APExBIO’s quality and cutting-edge reference data.

• Fenofibrate Activates PPARα-YAP Pathway for Liver Enlargemen

  2026-07-22

  A recent study demonstrates that fenofibrate, a PPARα agonist, induces liver enlargement in both adult and aging mice through activation of the PPARα-YAP signaling pathway. These findings reveal that the hepatic response to fenofibrate is age-independent, offering new mechanistic insight for metabolic and aging research.

• DMXAA (Vadimezan) as a STING-Targeted Vascular Disruptor: Ap

  2026-07-21

  DMXAA (Vadimezan) stands out as a potent vascular disrupting agent and apoptosis inducer, uniquely bridging anti-angiogenic and innate immune activation strategies in cancer biology. This article delivers practical workflows and troubleshooting guidance for leveraging DMXAA in advanced tumor models, with actionable insights from recent nanomedicine innovations.

• Gramine Induces Ferroptosis via CUL3–MTDH Ubiquitination in

  2026-07-21

  This study establishes Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a selective ferroptosis inducer in triple-negative breast cancer (TNBC) through modulation of the CUL3–MTDH ubiquitination axis. The findings highlight a mechanistic pathway for ferroptosis induction and offer important implications for targeted cancer biology research.

• Universal nPEC Method Optimizes Dual-Loaded Liposome Analysi

  2026-07-20

  The reference study introduces a nanoparticle exclusion HPLC (nPEC) method as an effective, accurate, and universally applicable strategy for determining the encapsulation efficiency of dual-loaded liposomes containing both hydrophilic and lipophilic drugs. This innovation addresses longstanding analytical challenges and supports reproducible nanomedicine workflows.

• GDC-0068 (RG7440): Pan-AKT Inhibition for Spatial Pathway Co

  2026-07-20

  Explore GDC-0068 (RG7440), a highly selective pan-AKT inhibitor, and its transformative applications in dissecting spatial compartmentalization within the PI3K/Akt/mTOR pathway. Uncover new insights for precision cancer research and advanced assay development.

• Abiraterone acetate (SKU A8202): Reliable CYP17 Inhibitor Wo

  2026-07-19

  This article guides biomedical researchers through real-world challenges in prostate cancer research, focusing on the reproducibility and mechanistic clarity offered by Abiraterone acetate (SKU A8202). By integrating scenario-driven Q&A and evidence-backed workflow recommendations, it empowers labs to optimize CYP17 inhibitor assays with confidence.

• Necrostatin-1: RIP1 Kinase Inhibitor Workflows & Optimizatio

  2026-07-18

  Necrostatin-1 is a gold-standard RIP1 kinase inhibitor, powering robust necroptosis assays and translational models of inflammation and tissue injury. This article delivers protocol enhancements, troubleshooting strategies, and insight into the latest viral-necroptosis crosstalk, all anchored by evidence and APExBIO’s trusted supply.

• Vitamin C as an Anticancer Agent: Workflows and Innovations

  2026-07-17

  Harnessing high-purity Vitamin C from APExBIO enables robust, reproducible workflows in cancer and senescence research. Learn how optimized protocols, troubleshooting strategies, and new mechanistic insights make ascorbic acid indispensable for tackling tumor proliferation and cellular aging.

• BMS-345541: Precision IKK-1/2 Inhibitor for Inflammation Res

  2026-07-17

  BMS-345541 (free base) enables targeted, reproducible inhibition of the NF-κB pathway for inflammation and cancer research. This article delivers workflow-ready protocols, troubleshooting strategies, and unique insights from recent angiogenesis studies, empowering advanced translational applications.

• Strategic Disruption of PI3K/Akt in Oncology with GDC-0941

  2026-07-16

  This thought-leadership article dissects the mechanistic and translational opportunities of PI3K/Akt pathway inhibition in cancer, focusing on GDC-0941. By blending biological rationale, evidence-based protocol guidance, and contemporary resistance insights—especially in the context of liver cancer stem cell phenotypes and therapy resistance—the piece provides actionable direction for translational researchers. It bridges recent landmark findings on DRD4-mediated chemo-resistance with practical workflow considerations, positioning GDC-0941 as a crucial tool for the next wave of therapeutic innovation.

11632 records 1/776 page Next 12345 下5页 Last page